Particle Sciences Rebrands as Lubrizol Life Science Health
Lubrizol Life Science Health adopts new name and opens commercial manufacturing facility.
Lubrizol Corporation announced on Nov. 5, 2019 that Particle Sciences, the company’s contract development and manufacturing organization (CDMO), was renamed Lubrizol Life Science Health (LLS Health), reflecting its incorporation into the new Lubrizol Life Science business group, which includes the Personal, Home, and Health Care business units.
The company also announced the opening of a new 5000-sq.-ft. commercial manufacturing facility in Bethlehem, PA., part of a $60 million investment. One of the first projects was the production of an aseptic fill to be incorporated into a novel sterile multi-use topical ophthalmic delivery device.
In a press statement, the company noted that these strategic moves demonstrate the company’s ongoing expansion of its “concept-to commercialization solutions” for medical device and pharmaceutical companies.
“As part of Lubrizol Life Science, we can share and draw upon the resources that come with being part of a large corporation to provide customers with greater support and the market insights that help them meet their goals,” said Barbara Morgan, global business director, Pharmaceutical Solutions, LLS Health in the press statement. “We are focused on expanding and strengthening our internal capabilities so we can continue to sustainably innovate the way we develop and manufacture drug products in partnership with customers, particularly those complex and differentiated products which require additional expertise and experience.”
“We have built a strong reputation for complex drug product expertise with a flexible and proactive approach to solving drug development challenges,” added Robert Lee, president, CDMO Division, LLS Health in the statement. “As LLS Health, this expertise and flexibility will continue, backed by the collective expertise of Lubrizol Life Science, and ongoing investments in our team and facilities.”
Source: Lubrizol Life Science
Ushering in Industry 4.0 with the IDMO Model to Solve the CGT Manufacturing Bottleneck
May 28th 2025Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
